MEI Pharma Inc (MEIP)

What You Need To Know About MEI Pharma, Inc.'s (NASDAQ:MEIP) Investor Composition - Yahoo Canada Shine On

Yahoo Canada Shine On

StockNews.com Begins Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World

Defense World

MEI Pharma, Inc. (MEIP) Shares March Higher, Can It Continue? - Yahoo News UK

Yahoo News UK

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP) - Business Wire

Business Wire

BAYRY: Top 4 Pharma Stocks to Consider This Month - StockNews.com

StockNews.com

MEI Pharma, Inc. (NASDAQ:MEIP) Is Expected To Breakeven In The Near Future - Yahoo Lifestyle UK

Yahoo Lifestyle UK

MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights - Business Wire

Business Wire

Revenue Downgrade: Here's What Analysts Forecast For MEI Pharma, Inc. (NASDAQ:MEIP) - Yahoo News UK

Yahoo News UK

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research

MEI Pharma, Inc. (MEIP) Reports Break-Even Earnings for Q4 - Yahoo Singapore News

Yahoo Singapore News

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Lifestyle Australia

Yahoo Lifestyle Australia

VTRS: 3 Pharma Stocks Outperforming the Competition - StockNews.com

StockNews.com

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Yahoo Finance

Biotech bankruptcies hit 10-year peak in 2023 - Fierce Biotech

Fierce Biotech

Is MEI Pharma (MEIP) Attractively Priced? - Yahoo Finance

Yahoo Finance

Kyowa Kirin enrols first subject in Phase II diabetic macular oedema trial - Clinical Trials Arena

Clinical Trials Arena

Fierce Biotech M&A Tracker 2023: BMS, AbbVie drop billions for neuropsychiatry biotechs - Fierce Biotech

Fierce Biotech

Infinity comes to an end with Chapter 11 bankruptcy filing - Fierce Biotech

Fierce Biotech

Anson Funds Management LP Acquires Shares in MEI Pharma Inc - Yahoo Finance

Yahoo Finance

Three execs leave Infinity Pharmaceuticals after failed merger, layoffs - The Business Journals

The Business Journals

Infinity lays off 78% of staff, 3 board members after MEI merger fails - Fierce Biotech

Fierce Biotech

Rebuffed by MEI Pharma, Infinity scuttles merger and may face bankruptcy - MM+M Online

MM+M Online

MEI Pharma Announces Results of Special Meeting of Stockholders - Business Wire

Business Wire

MEI Pharma CEO departs as company rejects unsolicited takeover bid - MM+M Online

MM+M Online

Infinity merger with MEI in doubt after surprise buyer makes bid - Fierce Biotech

Fierce Biotech

MEI Pharma Announces 1-for-20 Reverse Stock Split - Business Wire

Business Wire

Bankruptcy awaits Infinity Pharmaceuticals if MEI merger falters - MM+M Online

MM+M Online

Infinity Pharmaceuticals Reports Full Year 2022 Financial Results - Business Wire

Business Wire

Who's gone? A snapshot of biotechs closing doors - BioCentury

BioCentury

MEI Pharma Inc Company Profile - GlobalData

GlobalData

MEI Pharma And Infinity Pharmaceuticals Announce Merger (MEIP) (INFI) - Pulse 2.0

Pulse 2.0

MEI Pharma and Infinity Pharma ink all-stock merger deal (NASDAQ:MEIP) - Seeking Alpha

Seeking Alpha

MEI Abandons PI3K Inhibitor, 30% of Staff in Strategic Shift - BioSpace

BioSpace

Eisai, BeiGene, Shionogi—Fierce Pharma Asia - FiercePharma

FiercePharma

The Top 25 Healthcare Technology Leaders of San Diego for 2022 - The Healthcare Technology Report.

The Healthcare Technology Report.

40+ Key Companies Actively Working in the Marginal Zone Lymphoma Pipeline Segment | DelveInsight - GlobeNewswire

GlobeNewswire

MEI Pharma stock trades higher as FY22 revenue grows 17% - Seeking Alpha

Seeking Alpha

Vertex's Hughes moves to Teva - BioCentury

BioCentury

MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid ... - BioSpace

BioSpace

PI3K inhibitor survival data raise cancer trial design questions - BioCentury

BioCentury

FDA Informs Developers of Zandelisib of Need for Randomized Phase 3 Trial for Approval - Cancer Network

Cancer Network

Those who invested in MEI Pharma (NASDAQ:MEIP) five years ago are up 62% - Yahoo Canada Finance

Yahoo Canada Finance

MEI Pharma Announces Acceptance of Three Abstracts for Presentation at the 63rd Annual American Society of ... - Business Wire

Business Wire

MEI Pharma, Inc. (NASDAQ:MEIP) Is Expected To Breakeven In The Near Future - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Mei (MEIP) Begins Phase III Study for B-Cell Malignancies - Yahoo Singapore News

Yahoo Singapore News

MEI Pharma to Present at Two Upcoming Investor Healthcare Conferences - PR Newswire

PR Newswire

MEI Pharma Set To Explode With Announcement Of Lucrative Partnership (NASDAQ:MEIP) - Seeking Alpha

Seeking Alpha

MEI Pharma Announces Pricing of Public Offering of Common Stock - PR Newswire

PR Newswire

MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib - PR Newswire

PR Newswire